Given the divergent reports and conclusions about the true pathophysiological role of GREM1 in different human cancers, we would suggest caution in this approach, as any agent that increases the tone or volume of GREM1 signaling may exacerbate the cancer phenotype and potentially worsen patient outcomes (for example, see Jaeger et al. 2012). Here, GREM1 is linked to cancer.